A group from Nagoya University in Japan has developed a simple, accurate, and sensitive method for measuring polysialic acid, ...

Sanofi's antibody riliprubart has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare ...

Sanofi (NASDAQ: SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...

(NASDAQ:ARGX) is down ~7% in Monday trading after the U.S. FDA issued an alert on a potential signal of serious risks associated with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase). The agency ...

Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...

Sanofi (ENXTPA:SAN) recently received orphan drug designation from Japan's Ministry of Health for riliprubart, aimed at treating chronic inflammatory demyelinating polyneuropathy. This underscores the ...

One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

The US Food and Drug Administration (FDA) has approved Japanese pharma major Takeda’s Gammagard Liquid ERC [immune globulin ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy  Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...